Biology of Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Persistent Impairment in Immune Reconstitution and Worse Survival Outcomes Among Allogeneic Stem Cell Transplant Patients with Early COVID-19 Infection
Allogeneic hematopoietic stem cell transplantation (ASCT) is a curative procedure for a broad range of hematologic diseases. Patients are highly susceptible to infectious complications especially in the first 6-12 months post-transplant causing an increased risk of treatment-related mortality, at least in part due to the profound decrease in numbers and impaired function of T- and B-cells in the early post-transplant period1. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 4, 2024 Category: Hematology Authors: Benjamin J. Lee, Pongthep Vittayawacharin, Shawn P. Griffin, Jean Doh, Hannah H. Nam, Deepa Jeyakumar, Emily Blodget, Piyanuch Kongtim, Stefan O. Ciurea Source Type: research

Intensive Re-Induction Chemotherapy Followed by Early Allogeneic Hematopoietic Cell Transplant for Relapsed/Refractory High-Grade Myeloid Neoplasms
Despite recent advances in systemic therapy, most patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and other high-grade myeloid neoplasms continue to have poor outcomes, with allogeneic hematopoietic cell transplantation (HCT) remaining the only curative option.1 Since few adults transplanted with active disease survive long-term, salvage chemotherapy is typically given first to induce a complete remission (CR; (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 4, 2024 Category: Hematology Authors: Noam E. Kopmar, Megan Othus, Kim Quach, Allegra Rasmussen, Kelda Schonhoff, Pamela S. Becker, Roland B. Walter, Anna B. Halpern, Rachel Salit, Ryan D. Cassaday, Andrei Shustov, F. Marc Stewart, Vivian G. Oehler, Bart L. Scott, Brenda M. Sandmaier, Stephan Source Type: research

Comparison of older related vs younger unrelated donors for old recipients of allogeneic hematopoietic cell transplantation with AML or MDS- a large single center analysis
The introduction of reduced-intensity conditioning regimens has made allogeneic hematopoietic cell transplantation (alloHSCT) feasible for elderly recipients, aged well into their 70s1. In particular, myeloid malignancies such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), which are conventionally diseases of the elderly (median age at diagnosis ∼ 68 years for AML and ∼70 years for MDS), have become the most common disease indications for alloHCT, comprising 65-70% of all alloHCTs performed worldwide. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - May 2, 2024 Category: Hematology Authors: Haesook T. Kim, Vincent T Ho, Sarah Nikiforow, Corey Cutler, John Koreth, Roman M Shapiro, Mahasweta Gooptu, Rizwan Romee, Catherine J. Wu, Joseph H. Antin, Jerome Ritz, Robert J Soiffer Source Type: research

Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers
Large B-cell lymphoma (LBCL) is the most common type of non-Hodgkin lymphoma, with a US incidence rate of 5.5 per 100,000 men and women per year and a 5-year overall survival rate of 64.7%.1 Although two-thirds of patients with LBCL are cured with standard chemoimmunotherapy regimens, 30%-40% of patients will either have progression of disease or relapse after initial response.2,3 (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 30, 2024 Category: Hematology Authors: Nausheen Ahmed, Fang Sun, Christie Teigland, Karl M. Kilgore, Iman Mohammadi, John Chambers, Christopher Dieyi, Chaoling Feng, Jennifer Osborn, Christine Fu, Usama Gergis Source Type: research

Impact of Early Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation on Relapse in Patients with Myelodysplastic Syndrome: A Nationwide Retrospective Study from Adult Myelodysplastic Syndrome Working Group of the JSTCT
Cytomegalovirus (CMV) reactivation is a well-recognized major complication associated with morbidity and mortality in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT).1-5 Although different prophylactic and pre-emptive approaches have been developed to manage CMV reactivation in allogeneic HSCT recipients, several studies still emphasized the negative association between CMV reactivation and various post-transplant outcomes, including non-relapse mortality caused by infectious complications or graft-versus-host disease (GVHD) and overall survival. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 30, 2024 Category: Hematology Authors: Tatsuya Konishi, Kensuke Matsuda, Hidehiro Itonaga, Noriko Doki, Tetsuya Nishida, Ken-ichi Matsuoka, Takashi Ikeda, Yoshinobu Kanda, Takahiro Fukuda, Junya Kanda, Hirohisa Nakamae, Kazunori Imada, Yasunori Ueda, Tatsuo Ichinohe, Yoshiko Atsuta, Ken Ishiya Source Type: research

Outcomes of a Formal Hematopoietic Cell Transplantation Survivorship Program on Screening for Late Effects
Advances in the treatment of hematologic malignancies, allogeneic hematopoietic cell transplantation (HCT), and supportive care continue to improve post-HCT outcomes, and the number of long-term HCT survivors in the past decade has dramatically increased [1,2]. With improved post-HCT survival, it is increasingly important to consider late-treatment effects from chemotherapy and/or radiation and chronic graft-versus-host disease (GVHD) which may lead to decrements in quality of life and survival [3-5], especially since life expectancy post-HCT remains lower than that of the general population [2]. (Source: Biology of Blood ...
Source: Biology of Blood and Marrow Transplantation - April 27, 2024 Category: Hematology Authors: Richard A. Newcomb, Lucy Gao, Julie Vanderklish, Alexandra Tse, Meredith Saylor, Colleen Danielson, Nisha Wali, Matthew Frigault, Steven McAfee, Thomas Spitzer, Zachariah DeFilipp, Yi-Bin Chen, Hermioni L. Amonoo, Areej El-Jawahri Tags: Survivorship Source Type: research

Outcomes of a Formal Hematopoietic Cell Transplantation (HCT) Survivorship Program on Screening for Late Effects
Advances in the treatment of hematologic malignancies, allogeneic hematopoietic cell transplantation (HCT), and supportive care continue to improve post-HCT outcomes, and the number of long-term HCT survivors in the past decade has dramatically increased.1,2 With improved post-HCT survival, it is increasingly important to consider late-treatment effects from chemotherapy and/or radiation and chronic graft-vs-host disease (GVHD) which may lead to decrements in quality of life (QOL) and survival,3 –5 especially since life expectancy post-HCT remains lower than that of the general population. (Source: Biology of Blood and M...
Source: Biology of Blood and Marrow Transplantation - April 27, 2024 Category: Hematology Authors: Richard A. Newcomb, Lucy Gao, Julie Vanderklish, Alexandra Tse, Meredith Saylor, Colleen Danielson, Nisha Wali, Matthew Frigault, Steven McAfee, Thomas Spitzer, Zachariah DeFilipp, Yi-Bin Chen, Hermioni L. Amonoo, Areej El-Jawahri Source Type: research

Profile of a Pioneer: Robert A. Good
Often referred to as the founder of modern immunology, Robert Alan Good, MD, PhD (Figure 1) was an exceptionally productive immunologist and gifted physician. His discoveries distinguished the lymphoid lineages responsible for cell-mediated and humoral immunity, and he played a seminal role in the science and application of allogeneic marrow transplantation for curative treatment of genetic and acquired diseases of immunity and hematopoiesis. He was born in Crosby, MN, the second of four sons of teacher parents. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Authors: Richard J. O'Reilly Tags: Reflections Source Type: research

Biological Age is No Barrier for Adult Patients Undergoing CAR T for Non-Hodgkin's Lymphoma or Multiple Myeloma
The recent introduction of chimeric antigen receptor T cell therapy (CAR T) into clinical practice has radically shifted the treatment paradigm of relapse/refractory B-cell non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) .1 The current commercially available products including axicabtagene ciloleucel (axi-cel) ,2 tisagenlecleucel (tisa-cel) ,3 and lisocabtagene maraleucel (liso-cel) 4,5 for NHL and idcabtagene vicleucel (ide-cel) 6,7 and ciltacabtagene autoleucel f d(cilta-cel) 8 for MM have shown impressive response rates and survival outcomes in heavily pretreated patients who would otherwise have very limited treat...
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Authors: Danai Dima, Craig S. Sauter Tags: The Bottom Line Source Type: research

Thrombopoietin Agonism to Promote Platelet Engraftment Following Hematopoietic Stem Cell Transplantation: Promising, but Not Ready for Primetime
In this issue of TCT, Fu and colleagues report the results of a randomized clinical trial conducted in China comparing thrombopoietic support using recombinant human thrombopoietin (rhTPO) with observation to promote platelet engraftment in patients receiving haploidentical hematopoietic stem cell transplantation (HSCT) with post-transplantation cyclophosphamide for the treatment of severe aplastic anemia (SAA).1 The trial enrolled 55 patients, randomized 1:1 to rhTPO or observation. The authors report successful hematopoietic reconstitution in all patients, but significantly faster platelet engraftment in patients randomi...
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Authors: Hanny Al-Samkari Tags: The Bottom Line Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Officers and Directors of ASTCT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 26, 2024 Category: Hematology Source Type: research

Transplant-associated Altered Mentation and Encephalopathy (TAME): A New Classification for Acute Neurocognitive Changes Associated with Hematopoietic Cell Transplantation from the ASTCT Committee on Practice Guidelines
Acute encephalopathy, manifesting clinically as delirium, is a common but often unrecognized complication of hematopoietic cell transplant (HCT). Delirium is found in patients of any age and observed after autologous or allogeneic HCT. While primarily studied during initial transplant hospitalizations among recipients of myeloablative conditioning, recent HCT investigations have identified delirium later posttransplant and among those who received reduced intensity conditioning. Acute encephalopathy can be driven by infectious complications, medications, tissue damage and/or organ dysfunction. (Source: Biology of Blood and...
Source: Biology of Blood and Marrow Transplantation - April 23, 2024 Category: Hematology Authors: G. Meyers, J. Bubalo, E. Eckstrom, K. Winsnes, P.A. Carpenter, A. Artz, R.J. Lin Source Type: research